DDInter906 DDInter1676
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ifosfamide {u} (Compound) treats {v} (Disease) testicular cancer
Ifosfamide {u} (Compound) binds {v} (Gene) CYP2A6
Ifosfamide {u} (Compound) upregulates {v} (Gene) UBQLN2
Ifosfamide {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Ifosfamide {u} (Compound) downregulates {v} (Gene) STUB1
Ifosfamide {u} (Compound) causes {v} (Side Effect) Palpitations
Ifosfamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Ifosfamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quazepam
Ifosfamide (Compound) treats testicular cancer (Disease)
Ifosfamide (Compound) binds CYP2A6 (Gene)
Ifosfamide (Compound) upregulates UBQLN2 (Gene)
Ifosfamide (Compound) is included by Alkylating Activity (Pharmacologic Class)
Ifosfamide (Compound) downregulates STUB1 (Gene)
Ifosfamide (Compound) causes Palpitations (Side Effect)
Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Quazepam